T78.01XA

Anaphylactic reaction due to peanuts, initial encounter

Anaphylactic reaction due to peanuts is a severe, life-threatening type I hypersensitivity reaction (IgE-mediated) occurring rapidly upon exposure to peanut proteins. It is characterized by a systemic release of mediators from mast cells and basophils, leading to multisystem involvement. Peanuts (Arachis hypogaea) contain potent allergens such as Ara h 1, Ara h 2, and Ara h 3, which are particularly stable and resistant to heat and digestion, often leading to severe clinical outcomes. The initial encounter code (T78.01XA) is utilized when the patient is receiving active treatment for the anaphylactic event, which typically necessitates emergency medical intervention including the administration of intramuscular epinephrine, airway management, and hemodynamic support. This condition is distinct from non-IgE mediated food intolerances due to its rapid onset and potential for respiratory or circulatory collapse.

Clinical Symptoms

Urticaria (hives) and generalized pruritus
Angioedema, particularly of the lips, tongue, and throat
Respiratory distress including wheezing, stridor, or shortness of breath
Hypotension and tachycardia (signs of anaphylactic shock)
Nausea, vomiting, abdominal cramping, and diarrhea
Tightness in the chest or throat
Sense of impending doom
Cyanosis (bluish skin tint due to hypoxia)
Syncope or loss of consciousness
Dysphonia or hoarseness

Common Causes

Ingestion of peanuts or peanut-containing products
Accidental cross-contamination during food preparation
Inhalation of aerosolized peanut dust in confined spaces
Skin contact with peanut oils or proteins (less common for systemic reaction)
IgE-mediated sensitization to specific peanut proteins (Ara h 1-Ara h 17)
History of asthma (increases risk for severe/fatal reactions)
Previous mild allergic reactions to peanuts serving as a precursor
Delayed administration of epinephrine during an exposure event

Documentation & Coding Tips

Distinguish between initial and subsequent encounters by clinical status and active treatment phase.

Example: Patient presents with acute onset of respiratory distress and generalized urticaria following accidental peanut ingestion. This is the initial encounter for this life-threatening event. Administered 0.3mg Epinephrine IM. Diagnosis: T78.01XA. Risk adjustment: Acute life-threatening condition requiring emergency intervention.

Billing Focus: Episode of care suffix A for initial encounter during active treatment.

Document specific clinical manifestations of the anaphylactic reaction such as hypotension or airway compromise.

Example: Patient experienced wheezing and a drop in blood pressure to 80/50 mmHg immediately after peanut exposure. Documenting hypotension (I95.9) and bronchospasm (J98.01) alongside T78.01XA to show systemic involvement. Risk adjustment: Multiple organ system involvement increases clinical complexity.

Billing Focus: Code secondary manifestations to support medical necessity for higher-level E/M or emergency codes.

Clearly link the allergen (peanuts) to the reaction to ensure correct external cause coding and allergen specificity.

Example: Anaphylaxis occurred within 10 minutes of consuming a cookie containing peanut flour. This link is established by history and clinical presentation. Patient has a known history of Z91.010 (Allergy to peanuts). Risk adjustment: Establishing causal link supports the specificity required for precise HCC grouping.

Billing Focus: The seventh character A must be used for the first time the patient is seen for this acute injury.

Include details on the route of exposure such as ingestion, inhalation, or skin contact.

Example: Anaphylactic reaction occurred via ingestion of peanut-contaminated food. Treatment included IV fluids for hypotension and intramuscular epinephrine. Risk adjustment: Ingestion-based anaphylaxis typically requires longer observation periods and higher resource utilization.

Billing Focus: Route of exposure provides context for the severity and potential for biphasic reactions.

Document the absence or presence of biphasic reactions during the observation period.

Example: Initial symptoms resolved after epinephrine, but patient was monitored for 8 hours for a biphasic reaction. No recurrence of symptoms noted. Risk adjustment: Monitoring for complications like biphasic reactions demonstrates high-level management of a life-threatening condition.

Billing Focus: Observation time and monitoring are critical for coding intensive care or prolonged observation services.

Relevant CPT Codes

99285 - Emergency department visit for the evaluation and management of a patient, which requires a high level of medical decision making
Anaphylaxis is a life-threatening emergency requiring high-level MDM and immediate intervention.
99215 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a high level of medical decision making or 40-54 minutes of total time
Used for complex follow-up visits where multiple comorbidities or severe reaction history must be managed.
99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a moderate level of medical decision making or 30-39 minutes of total time
Standard follow-up for stable patients to review epinephrine use and avoidance strategies.
99213 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a low level of medical decision making or 20-29 minutes of total time
Used for routine monitoring or prescription refills in stable patients.
95115 - Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection
While not for acute anaphylaxis, this is relevant for patients undergoing desensitization therapy.
95004 - Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, number of tests
Used to confirm peanut allergy after the initial acute event has resolved.
94640 - Pressurized or nonpressurized inhalation treatment for acute airway obstruction or for therapeutic purposes and unit dose training
Often required for bronchospasm associated with anaphylaxis.
96372 - Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
The procedure code for administering epinephrine in a clinical setting.
96360 - Intravenous infusion, hydration; initial, 31 minutes to 1 hour
Necessary for treating hypotension and shock during anaphylaxis.
99212 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a straightforward level of medical decision making or 10-19 minutes of total time
Minimal visits for simple documentation or results review.